Five independent groups have developed frameworks to assess the value of prescription drugs. The assessment results are filtering into business and clinical practices in the New Health Economy. Third party not-for-profit organizations promising independent, scientific and transparent drug value assessments are the newest voice in a national debate about drug prices. Insurers, pharmacy benefits managers and health systems are beginning to use these value assessments for structuring drug benefits and negotiating prices. Many drug manufacturers, however, are challenging what they consider a flawed methodology for product assessment and have recommended changes to the assessment frameworks.
PwC’s Pharmaceutical and life sciences works with you from strategy through execution. Discover other ways we’ll help you succeed in the New Health Economy.
US Pharmaceutical and Life Sciences Leader, PwC US
Global Pharmaceutical and Life Sciences Advisory Leader, PwC US